Anteris Technologies Global Corp

AVR

4.030USD

-0.180-4.28%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

Anteris Technologies Global Corp's Score

Industry at a Glance

Industry Ranking

111 / 210

Overall Ranking

265 / 4615

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

16.500

Target Price

+291.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Anteris Technologies Global Corp Highlights

StrengthsRisks

Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.70M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.70M.

Overvalued

The company’s latest PE is -1.90, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 17.20M shares, decreasing 23.94% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 402.85K shares of this stock.

The company's current financial score is 6.31, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.31

Change

0



Financials

8.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.43

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 7.95, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -1.90, which is -5.71% below the recent high of -1.79 and -114.76% above the recent low of -4.08.

Score

Industry at a Glance

Previous score

7.95

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 111/210

No Data

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Anteris Technologies Global Corp is 17.50, with a high of 22.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.43, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 5.65 and the support level at 3.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

-0.04

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

L1 Capital Pty Ltd.

2.81M

-59.17%

Sio Capital Management, LLC

1.84M

-22.40%

Perceptive Advisors LLC

1.71M

-20.32%

Nantahala Capital Management, LLC

1.69M

+1.80%

Ensign Peak Advisors, Inc.

1.44M

+0.02%

Rhenman & Partners Asset Management AB

1.25M

-3.04%

J.P. Morgan Securities LLC

1.06M

+29978.79%

BlackRock Institutional Trust Company, N.A.

930.05K

+182.37%

Alyeska Investment Group, L.P.

550.00K

--

Adar1 Capital Management LLC

531.51K

-68.33%



1

2



The company’s current risk assessment score is 1.92, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Anteris Technologies Global Corp

AVR

6.15 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Castle Biosciences Inc

CSTL

8.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

TCMD

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Artivion Inc

AORT

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment